key: cord-1047888-8wrixmw8 authors: Ashford, J. Wesson; Gold, Jeffrey E.; Huenergardt, MaryJane A.; Katz, Ronit BA; Strand, Susanne E.; Bolanos, Joe; Wheeler, Christopher J.; Perry, George; Smith, Carr J.; Steinman, Lawrence; Chen, Mike Y.; Wang, Jeffrey C.; Ashford, Clinton B.; Roth, Walton T.; Cheng, Jauhtai Joseph; Chao, Steven; Jennings, Jennifer; Sipple, Daniel; Yamamoto, Vicky; Kateb, Babak; Earnest, David L. title: MMR Vaccination: A Potential Strategy to Reduce Severity and Mortality of COVID-19 Illness date: 2020-10-23 journal: Am J Med DOI: 10.1016/j.amjmed.2020.10.003 sha: b453d952da2932ac8f1a95c47f5f55a5bfc1cb9f doc_id: 1047888 cord_uid: 8wrixmw8 nan After a large jump from 5 to 20 years of age, the death rate increased for those over 30 at an exponential age-related rate, doubling every 7.4 years. This rate exceeds the base rate of the exponential increase of total deaths with age (only doubling every 9 years after age 30, see Ashford 7 ). Accordingly, the vulnerability to COVID-19 is closely related to age but exceeds the increase of the established comorbid illnesses (obesity, hypertension, diabetes, vascular disease) with age. Unexpectedly, the percentage of COVID-19 deaths relative to all deaths increases most sharply between 15 and 45 years, but over 45 there is a relatively stable percentage of COVID-19 deaths in this older population, ranging between 8.4%-9.8%. This discrepancy suggests that the strong relationship with comorbidities occurs because of a confound with age while some other factor is causally involved. As observed internationally, MMR vaccination could also potentially contribute to the US age distribution. The low infection rates and mild presentations in children >one year of age may be due to childhood vaccinations. The CDC recommends that children get two MMR doses, at 12-15 months of age and 4-6 years. Double childhood MMR vaccination can generate antibodies lasting for 20 or more years 8 . Yet, some children do not get vaccinated at all 5 . Further, long-term benefit declines with age, as evidenced by many women presenting for prenatal care who have lost MMR-related immunity 9 . This pattern is consistent with the observed progressive increase of COVID-19 infection and death rates up to 45 years of age (CDC data). The stabilization of the percentage increase in COVID-19 mortality with more advanced age may be due to long-lasting immune responses to now-rare childhood infections 10 , but which are less protective against COVID-19. 3) There are reports that appear to suggest that several currently available vaccines already established as "safe" (including polio, Hemophilus influenzae type-B (HiB), MMR, and pneumococcal), may offer significant protection against COVID-19 via a non-specific "innate immunity" 11, 12, 13 . However, these findings may actually be reflecting a response to MMR vaccination, which is often administered in conjunction with these others. More directly, there is evidence that rubella virus has a 29% sequence homology with a SARS-CoV-2 surface protein 3, 14 . Accordingly, the rubella component of the MMR vaccine may confer specific protection against COVID-19. These findings suggest the MMR vaccine may protect against COVID-19, including high-risk individuals, such as elderly with co-morbidities, health care workers and first-responders with COVID-19 patients, especially individuals living in long-term care facilities and the related institutional staff. Clinicians who are caring for such high-risk persons should consider the benefit/cost ratios of MMR vaccination to justify use of this simple, low risk intervention to reduce COVID-19 disease, especially until a specific vaccine is approved. Clinical trials to confirm this speculation are now being conducted. COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications MMR Vaccine Appears to Confer Strong Protection from COVID-19: Few Deaths from SARS-CoV-2 in Highly Vaccinated Populations Homologous protein domains in SARS-CoV-2 and measles, mumps, and rubella viruses: preliminary evidence than MMR vaccine might provide protection against COVID-19 Progress Toward Measles Elimination -China Confirmatory bias in health decisions: Evidence from the MMR-autism controversy Strengthening vaccination programmes and health systems in the European Union: A framework for action APOE genotype effects on Alzheimer's disease onset and epidemiology Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up Rubella, rubeola, and mumps in pregnant women: susceptibilities and strategies for testing and vaccinating Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection? Exploratory analysis of immunization records highlights decreased SARD-CoV-2 rates in individuals with recent non-COVIC-19 vaccinations Age and Location in Severity of COVID-19 Pathology: Do Lactoferrin and Pneumococcal Vaccination Explain Low Infant Mortality and Regional Differences? Does Early Childhood Vaccination Protect Against COVID-19?